AQR Capital Management LLC lowered its position in Amedisys, Inc. (NASDAQ:AMED – Free Report) by 13.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,654 shares of the health services provider’s stock after selling 1,014 shares during the quarter. AQR Capital Management LLC’s holdings in Amedisys were worth $611,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently modified their holdings of the business. Arizona State Retirement System grew its holdings in Amedisys by 2.0% during the second quarter. Arizona State Retirement System now owns 9,145 shares of the health services provider’s stock worth $840,000 after acquiring an additional 177 shares during the period. Bridge City Capital LLC boosted its position in shares of Amedisys by 0.8% in the first quarter. Bridge City Capital LLC now owns 29,861 shares of the health services provider’s stock worth $2,752,000 after buying an additional 231 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Amedisys by 0.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,199 shares of the health services provider’s stock worth $2,876,000 after acquiring an additional 255 shares in the last quarter. Texas Permanent School Fund Corp increased its holdings in shares of Amedisys by 1.4% in the 1st quarter. Texas Permanent School Fund Corp now owns 28,560 shares of the health services provider’s stock valued at $2,632,000 after purchasing an additional 381 shares during the period. Finally, Commonwealth Equity Services LLC grew its position in Amedisys by 10.9% during the second quarter. Commonwealth Equity Services LLC now owns 4,151 shares of the health services provider’s stock valued at $381,000 after purchasing an additional 409 shares in the last quarter. Institutional investors own 94.36% of the company’s stock.
Amedisys Stock Performance
NASDAQ AMED opened at $96.33 on Monday. Amedisys, Inc. has a twelve month low of $89.55 and a twelve month high of $98.95. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.30. The company’s 50-day simple moving average is $97.27 and its 200 day simple moving average is $95.24. The stock has a market cap of $3.15 billion, a P/E ratio of -150.52, a PEG ratio of 1.89 and a beta of 0.78.
Analysts Set New Price Targets
A number of research firms recently commented on AMED. William Blair downgraded Amedisys from an “outperform” rating to a “market perform” rating in a report on Monday, July 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $101.00 target price on shares of Amedisys in a report on Thursday, July 25th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price target for the company. in a report on Monday, July 29th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $100.67.
Read Our Latest Stock Report on AMED
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
See Also
- Five stocks we like better than Amedisys
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- How to buy stock: A step-by-step guide for beginnersÂ
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMED – Free Report).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.